Despite the apparent diversity of the subcellular systems involved in the mechanism of acquired resistance to rilotumumab, its rapid development suggests that GBM cells in which HGF is an important oncogenic driver are predisposed to its adaptation as a route to survival. Here, HGF is linked to glioblastoma.